Spots Global Cancer Trial Database for scchn
Every month we try and update this database with for scchn cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00402545 | Head and Neck N... | Cetuximab Docetaxel Cisplatin 5-Fluorouracil | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00409565 | Head and Neck C... Squamous Cell C... | Cetuximab Bevacizumab | 18 Years - 98 Years | National Cancer Institute (NCI) | |
| Sexual Behavior in Head and Neck Cancer Patients | NCT00662662 | Oropharyngeal C... Head and Neck C... Squamous Cell C... | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Study of PX-866 and Docetaxel in Solid Tumors | NCT01204099 | Non Small Cell ... Squamous Cell C... | Docetaxel PX-866 | 18 Years - | Seagen Inc. | |
| Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN | NCT01305772 | Squamous Cell C... | Panitumumab Surgery Radiation Thera... | 18 Years - | Duke University | |
| Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer | NCT02350712 | Squamous Cell C... | Patritumab Cetuximab Cisplatin Carboplatin | 18 Years - | Daiichi Sankyo | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck | NCT00459043 | Squamous Cell C... | ZD6474 Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | NCT02777385 | Head and Neck S... | Pembrolizumab Cisplatin IMRT | 18 Years - | University of Pittsburgh | |
| Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT01836029 | Carcinoma, Squa... | VTX-2337 Carboplatin Cisplatin 5-fluorouracil Placebo | 18 Years - | Celgene | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck | NCT02236936 | Squamous Cell C... Squamous Cell C... Laryngeal Squam... Laryngeal Squam... Oropharyngeal S... Oropharyngeal S... Squamous Cell C... Squamous Cell C... Locally Advance... | Standard care o... Parenteral over... Cetuximab Cisplatin Radiotherapy | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection | NCT01927744 | Head and Neck C... | Docetaxel Erlotinib Placebo Questionnaires Phone Call Chemotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | NCT04925284 | Non Small Cell ... Cervical Cancer SCCHN Pancreatic Canc... Esophageal SCC Metastatic Cast... Triple Negative... Hormone Recepto... Epithelial Ovar... Endometrial Can... Tissue Factor-E... | XB002 Nivolumab | 18 Years - | Exelixis | |
| SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes | NCT02644122 | Metastatic Squa... | SF1126 | 18 Years - | University of California, San Diego | |
| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | NCT05077709 | Lung Cancer Non... Head and Neck S... Urothelial Carc... | IO102-IO103 in ... | 18 Years - | IO Biotech | |
| Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | NCT00080028 | Head and Neck C... Oropharynx Canc... Larynx Cancer Hypopharynx Can... | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00402545 | Head and Neck N... | Cetuximab Docetaxel Cisplatin 5-Fluorouracil | 18 Years - | Dana-Farber Cancer Institute | |
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT05359692 | Metastatic Head... Advanced Malign... Recurrent Head ... | INCAGN01876 retifanlimab | 18 Years - 99 Years | Incyte Corporation | |
| Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck | NCT02769520 | Squamous Cell C... | Pembrolizumab | 18 Years - | University of California, San Diego | |
| A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck | NCT03620123 | Recurrent or Me... Carcinoma, Squa... | Nivolumab and I... Docetaxel | 18 Years - | AIO-Studien-gGmbH | |
| Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | NCT04065555 | Head and Neck C... | TAK-981 Cetuximab Avelumab TAK-981 + Cetux... TAK-981 + Avelu... | 18 Years - | Presage Biosciences | |
| Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck | NCT00459043 | Squamous Cell C... | ZD6474 Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma | NCT01794845 | Squamous Cell C... Head and Neck C... Recurrent Disea... | Erbitux Taxotere Low Dose Fracti... | - | University of Miami | |
| Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT01836029 | Carcinoma, Squa... | VTX-2337 Carboplatin Cisplatin 5-fluorouracil Placebo | 18 Years - | Celgene | |
| Sexual Behavior in Head and Neck Cancer Patients | NCT00662662 | Oropharyngeal C... Head and Neck C... Squamous Cell C... | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 and 2 Study of PX-866 and Cetuximab | NCT01252628 | Incurable Metas... Incurable Progr... | PX-866 (SCCHN) Cetuximab (SCCH... PX-866 (CRC) Cetuximab (CRC) | 18 Years - | Seagen Inc. | |
| A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | NCT05323656 | Squamous Cell C... | Setanaxib Pembrolizumab Placebo | 18 Years - | Calliditas Therapeutics AB | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | NCT04844073 | Squamous Cell C... Non-small Cell ... Colorectal Canc... | TAK-186 | 18 Years - | Takeda | |
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck | NCT02236936 | Squamous Cell C... Squamous Cell C... Laryngeal Squam... Laryngeal Squam... Oropharyngeal S... Oropharyngeal S... Squamous Cell C... Squamous Cell C... Locally Advance... | Standard care o... Parenteral over... Cetuximab Cisplatin Radiotherapy | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | NCT03440437 | Advanced Cancer Metastatic Canc... Squamous Cell C... | FS118 Paclitaxel | 18 Years - | invoX Pharma Limited | |
| Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | NCT04997902 | HNSCC | Tipifarnib Alpelisib | 18 Years - | Kura Oncology, Inc. | |
| Dose Escalating Study for Amphinex-based PCI of Bleomycin. | NCT01872923 | Cutaneous or Su... | Amphinex Bleomycin Laser | 18 Years - | PCI Biotech AS | |
| Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer | NCT00101582 | Mucositis Solid Tumors Stomatitis Head and Neck C... Squamous Cell C... | Placebo palifermin cisplatin chemo... Radiotherapy | 18 Years - | Swedish Orphan Biovitrum | |
| Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | NCT00392665 | Squamous Cell C... | Bevacizumab erlotinib Sulindac | 18 Years - | Massachusetts General Hospital | |
| SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes | NCT02644122 | Metastatic Squa... | SF1126 | 18 Years - | University of California, San Diego | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors | NCT01963715 | EGFR Positive S... | IMGN289 | 18 Years - | ImmunoGen, Inc. | |
| A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck | NCT03620123 | Recurrent or Me... Carcinoma, Squa... | Nivolumab and I... Docetaxel | 18 Years - | AIO-Studien-gGmbH | |
| Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00547157 | Cancer Head and Neck C... Oncology Squamous Cell C... | Panitumumab Cisplatin | 18 Years - | Amgen | |
| Chemo-embolization for Head and Neck Cancer | NCT04595981 | SCCHN Squamous Cell C... | Cisplatin | 18 Years - | University of Alabama at Birmingham | |
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT05359692 | Metastatic Head... Advanced Malign... Recurrent Head ... | INCAGN01876 retifanlimab | 18 Years - 99 Years | Incyte Corporation | |
| Study of PX-866 and Docetaxel in Solid Tumors | NCT01204099 | Non Small Cell ... Squamous Cell C... | Docetaxel PX-866 | 18 Years - | Seagen Inc. | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. | |
| A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | NCT03241173 | Advanced Malign... | INCAGN01949 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection | NCT01927744 | Head and Neck C... | Docetaxel Erlotinib Placebo Questionnaires Phone Call Chemotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer | NCT02052960 | Carcinoma, Squa... | CetuGEX™ Cetuximab Chemotherapy | 18 Years - | Glycotope GmbH | |
| CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | NCT04891718 | Solid Tumour | MVC-101 Nivolumab MVC-101 + Nivol... | 18 Years - | Presage Biosciences | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | NCT05233436 | Advanced Solid ... Gastric Cancer Gastroesophagea... Urothelial Canc... Non Small Cell ... Head and Neck S... | PF-07265028 Sasanlimab | 18 Years - 99 Years | Pfizer | |
| A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe | NCT05123950 | Squamous Cell C... | 18 Years - | Bristol-Myers Squibb | ||
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN | NCT01305772 | Squamous Cell C... | Panitumumab Surgery Radiation Thera... | 18 Years - | Duke University | |
| Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | NCT04129320 | Head and Neck C... Squamous Cell C... | enoblituzumab MGA012 MGD013 | 18 Years - | MacroGenics | |
| Phase 1 and 2 Study of PX-866 and Cetuximab | NCT01252628 | Incurable Metas... Incurable Progr... | PX-866 (SCCHN) Cetuximab (SCCH... PX-866 (CRC) Cetuximab (CRC) | 18 Years - | Seagen Inc. | |
| Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen | NCT03771820 | SCCHN | NC-6004 Pembrolizumab | 18 Years - | NanoCarrier Co., Ltd. | |
| A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors | NCT01963715 | EGFR Positive S... | IMGN289 | 18 Years - | ImmunoGen, Inc. | |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | NCT03454451 | Non-Small Cell ... Renal Cell Canc... Colorectal Canc... Triple Negative... Cervical Cancer Ovarian Cancer Pancreatic Canc... Endometrial Can... Sarcoma Squamous Cell C... Bladder Cancer Metastatic Cast... Non-hodgkin Lym... | CPI-006 CPI-006 + cifor... CPI-006 + pembr... CPI-006 CPI-006 + cifor... CPI-006 + pembr... | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT01836029 | Carcinoma, Squa... | VTX-2337 Carboplatin Cisplatin 5-fluorouracil Placebo | 18 Years - | Celgene | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | NCT05233436 | Advanced Solid ... Gastric Cancer Gastroesophagea... Urothelial Canc... Non Small Cell ... Head and Neck S... | PF-07265028 Sasanlimab | 18 Years - 99 Years | Pfizer | |
| Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | NCT04881045 | Non-Small Cell ... Squamous Cell C... Ovarian Cancer | PF-07257876 | 18 Years - | Pfizer | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. | |
| A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | NCT05121948 | Squamous Cell C... Colo-rectal Can... Non Small Cell ... Transitional Ce... Other Solid Tum... Clear Cell Rena... | HC-7366 | 18 Years - | HiberCell, Inc. | |
| A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck | NCT04830592 | Squamous Cell C... | NG-641 Pembrolizumab | 18 Years - | Akamis Bio | |
| TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors | NCT01245985 | Locally Advance... | carbon ion boos... | 18 Years - 70 Years | Heidelberg University | |
| Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | NCT04065555 | Head and Neck C... | TAK-981 Cetuximab Avelumab TAK-981 + Cetux... TAK-981 + Avelu... | 18 Years - | Presage Biosciences | |
| Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00547157 | Cancer Head and Neck C... Oncology Squamous Cell C... | Panitumumab Cisplatin | 18 Years - | Amgen | |
| Chemo-embolization for Head and Neck Cancer | NCT04595981 | SCCHN Squamous Cell C... | Cisplatin | 18 Years - | University of Alabama at Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
